Stock BELL BELLUSCURA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Belluscura plc

Equities

BELL

GB00BD3B8Z11

Market Closed - London S.E.
Other stock markets
 11:35:20 2024-05-01 am EDT 		5-day change 1st Jan Change
7.25 GBX 0.00% Intraday chart for Belluscura plc -3.33% -68.48%
Apr. 02 Belluscura sees financial hit from delay to closing TMT acquisition AN
Apr. 02 AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist AN

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an enterprise value anticipated at 6.31 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
BELLUSCURA PLC Stock Belluscura plc
-68.48% 14.99M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.43% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.81% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.15% 67.78B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.43% 50.66B
B-
CENCORA, INC. Stock Cencora, Inc.
+11.60% 47.64B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.46% 41.12B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.03% 26.3B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+3.21% 26.04B
A-
TERUMO CORPORATION Stock Terumo Corporation
+15.69% 25.4B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BELL Stock
  4. Ratings Belluscura plc